{"disease":{"id":"nonalcoholic-steatohepatitis","name":"nonalcoholic steatohepatitis"},"drugs":{"marketed":[{"drug_id":"resmetirom","indication_name":"Noncirrhotic Nonalcoholic Steatohepatitis (NASH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RESMETIROM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Thyroid Hormone Receptor beta Agonist [EPC]","quality_score":30,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"pf-05221304","indication_name":"Nonalcoholic steatohepatitis (NASH)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-05221304","generic_name":"pf-05221304","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Acetyl-CoA carboxylase (ACC1 and ACC2)","drug_class":"Acetyl-CoA carboxylase inhibitor","quality_score":27,"revenue":null,"mechanism":"Selective inhibitor of acetyl-CoA carboxylase (ACC1/ACC2) that reduces hepatic lipogenesis and promotes fatty acid oxidation."}],"offLabel":[],"totalMarketed":1,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT07336563","title":"ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Jarosław Drobnik","has_results":false},{"nct_id":"NCT04442334","title":"The European NAFLD Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Newcastle University","has_results":false},{"nct_id":"NCT04371042","title":"PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05029583","title":"Clinical Outcomes From Enhanced SCREENing Strategies for NASH in Type 2 Diabetes (SCREEN NASH T2D)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"LMC Diabetes & Endocrinology Ltd.","has_results":false},{"nct_id":"NCT03028740","title":"AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1778,"lead_sponsor_name":"Tobira Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03726827","title":"A Self Selected Population Study of Undiagnosed NAFLD and NASH, Using an Echosens FibroScan, in at Risk Populations","phase":"","overall_status":"COMPLETED","enrollment_count":1006,"lead_sponsor_name":"Fatty liver Foundation","has_results":false},{"nct_id":"NCT04849728","title":"A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Inventiva Pharma","has_results":false},{"nct_id":"NCT03439254","title":"Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":919,"lead_sponsor_name":"Intercept Pharmaceuticals","has_results":true},{"nct_id":"NCT03053063","title":"Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":883,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT03053050","title":"Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":808,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT03289897","title":"Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan","phase":"NA","overall_status":"COMPLETED","enrollment_count":801,"lead_sponsor_name":"Perspectum","has_results":false},{"nct_id":"NCT04841057","title":"Biometabolic Outcomes After Weight Loss Surgery: An Individualized Approach","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":750,"lead_sponsor_name":"University of Missouri-Columbia","has_results":false},{"nct_id":"NCT04595474","title":"Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":533,"lead_sponsor_name":"Joslin Diabetes Center","has_results":false},{"nct_id":"NCT04653103","title":"NASH in Subjects With Different Classes of Obesity","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Catholic University of the Sacred Heart","has_results":false},{"nct_id":"NCT04971785","title":"Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":457,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT05479721","title":"LITMUS Imaging Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":450,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT04012242","title":"Innovative Liver Elasticity, Attenuation, and Dispersion Ultrasound Study","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Tokyo Medical University","has_results":false},{"nct_id":"NCT05023044","title":"Nonalcoholic Fatty Liver Disease in HIV Database","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT03449446","title":"Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":395,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT05877547","title":"A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":381,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04365868","title":"Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":357,"lead_sponsor_name":"Galectin Therapeutics Inc.","has_results":false},{"nct_id":"NCT03439189","title":"Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14","phase":"","overall_status":"COMPLETED","enrollment_count":343,"lead_sponsor_name":"Meridian Bioscience, Inc.","has_results":true},{"nct_id":"NCT03858920","title":"The Liver in the World Trade Center Health Program General Responder Cohort and Controls","phase":"","overall_status":"COMPLETED","enrollment_count":340,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false},{"nct_id":"NCT03151798","title":"The Liver Health Study for Patients with NAFLD","phase":"NA","overall_status":"COMPLETED","enrollment_count":336,"lead_sponsor_name":"University of Missouri-Columbia","has_results":false},{"nct_id":"NCT03248882","title":"Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":305,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04255069","title":"A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"TaiwanJ Pharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT05499949","title":"The Franciscus Obesity NASH Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Franciscus Gasthuis","has_results":false},{"nct_id":"NCT02217475","title":"Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":289,"lead_sponsor_name":"Tobira Therapeutics, Inc.","has_results":true},{"nct_id":"NCT04321031","title":"Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":256,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02443116","title":"Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":254,"lead_sponsor_name":"NGM Biopharmaceuticals, Inc","has_results":true},{"nct_id":"NCT04173065","title":"A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":248,"lead_sponsor_name":"Viking Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04880031","title":"A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":231,"lead_sponsor_name":"Boston Pharmaceuticals","has_results":false},{"nct_id":"NCT04054310","title":"Non-Invasive Quantification of Liver Health in NASH (N-QUAN)","phase":"NA","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Perspectum","has_results":false},{"nct_id":"NCT04561895","title":"Adipokine Genetic Variations in predictingNAFLD Progression to NASH in Egyptian Patients","phase":"","overall_status":"COMPLETED","enrollment_count":224,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT04929483","title":"Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":222,"lead_sponsor_name":"89bio, Inc.","has_results":true},{"nct_id":"NCT05809934","title":"A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02781584","title":"Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT05623189","title":"HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":218,"lead_sponsor_name":"HighTide Biopharma Pty Ltd","has_results":false},{"nct_id":"NCT04505436","title":"Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":215,"lead_sponsor_name":"Hanmi Pharmaceutical Company Limited","has_results":false},{"nct_id":"NCT04773964","title":"Study to Evaluate MET642 in Patients With NASH","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":215,"lead_sponsor_name":"Metacrine, Inc.","has_results":false},{"nct_id":"NCT05330923","title":"Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT03602573","title":"Liver Fibrosis in Peri-menopausal Women","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT04801849","title":"Vitamin E Dosing Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":true},{"nct_id":"NCT03486899","title":"A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":197,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT04166773","title":"A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":190,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT05011305","title":"Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":189,"lead_sponsor_name":"Zydus Therapeutics Inc.","has_results":false},{"nct_id":"NCT04583423","title":"A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":183,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03551522","title":"A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":181,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT05692492","title":"A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":180,"lead_sponsor_name":"Guangdong Raynovent Biotech Co., Ltd","has_results":false},{"nct_id":"NCT03534141","title":"Mild Hypothermia and Acute Kidney Injury in Liver Transplantation","phase":"NA","overall_status":"TERMINATED","enrollment_count":175,"lead_sponsor_name":"University of California, San Francisco","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}